Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

The present invention provides a vasodilator composition capable of adjusting a dosage of nitric oxide (NO). A vasodilator composition of the present invention includes microbubbles, wherein the microbubbles contain NO as a gas component.

Nanostructure lipid carriers, delivery systems, methods of making nanostructured lipid carriers and delivery systems, and methods of using the same are disclosed. A composition is disclosed and comprises at least one nanostructured lipid carrier, the nanostructured lipid carrier comprising a shell comprising an emulsifier, and an inner matrix comprising a solid lipid and a liquid lipid, wherein the nanostructured lipid carrier has a diameter of 50 nm or less.

The present invention chiefly aims to provide a new API particle in which a metal or the like is coated on the API itself of a pharmaceutical solid dosage form.

The present invention includes, for example, a coated API particle, wherein the surface of an API particle is coated with a metal or a metal oxide (e.g., iron oxide) by sputter deposition, and a process for manufacturing a pharmaceutical solid dosage form (e.g., tablet) using the coated API particles.

According to the present invention, for example, it is possible to improve the photostability of an API itself or of pharmaceutical solid dosage forms produced with the API.

This disclosure pertains to coated drug compositions and methods of preparing coated drug compositions with a low temperature silicon oxide coating. Specifically, the instant application discloses a method to coat active pharmaceutical ingredient particles using a silicon precursor and a catalyst at a low temperature.

A method of producing embolic particles includes forming a master batch of embolic particles, wherein the master batch of particles includes a plurality of negatively charged loading sites. The method also includes modifying the master batch of particles to form an activated batch of particles by reacting the master patch of particles with a bridging agent. The activated batch of particles includes a plurality of activated loading sites configured to bond to a negatively charged drug.

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

An industrially scalable microcapsule, fiber or film forming process and formulations suitable for use in conventional spray drying systems are provided. The one-step spray drying process utilizes formulations of a first ionic polymer, a second ionic polymer with an isoelectric point (pI.sub.2) or acid dissociation constant (pKa.sub.2) that is greater than the isoelectric point (pI.sub.1) or acid dissociation constant (pKa.sub.1) of the first ionic polymer and a volatile base or volatile acid. Volatilization of the volatile base or acid of the spray formulation changes the pH of the solution and changes the charge of the second ionic polymer initiating electrostatic interactions with the first ionic polymer through complex coacervation. Microcapsules formed by the complex coacervation process can stabilize bioactive components as well as control the release of the bioactive components for a variety of applications.

A process for producing a pharmaceutical formulation comprising the steps of: A) providing particles of a polymer, wherein particles of a pharmaceutical active substance are additionally at least partially embedded in the particles of the polymer; B) heating the particles of the polymer to a predetermined temperature for a predetermined time and C) cooling the particles of the polymer after the predetermined time to a temperature of 18° C. to 24° C., wherein the polymer is at least partially soluble in water and the active substance is at least partially soluble in the polymer.

The particulate pharmaceutical active substance is present in the form of particles having a d.sub.90 value in the particle size distribution of ≤1 μm. The predetermined temperature is within a range from 10 K below the glass transition temperature (determined by DSC in accordance with DIN EN ISO 11357-2 at a heating rate of 10 K/min) of the polymer to the melting temperature of the active substance. The total proportion of the active substance in the polymer is greater than the amount of active substance soluble in the polymer at the predetermined temperature.

The invention further relates to a pharmaceutical formulation comprising a particulate pharmaceutical active substance coated with an at least partially water-soluble polymer, to a process for producing a suspension of a pharmaceutical formulation and to a suspension of a pharmaceutical active substance.

Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.